文献速递乳腺PET

光声成像同时检测HER2阳性乳腺肿瘤中多种靶向金纳米颗粒

Simultaneous Detection of Multiple Tumor-targeted Gold Nanoparticles in HER2-Positive Breast Tumors Using Optoacoustic Imaging.
PubMed 文献 · Radiol Imaging Cancer · 2023-01-01

研究合成光谱可区分的靶向金纳米颗粒探针TRA-Aurelia-1和2,在MSOT下对人HER2阳性与阴性乳腺肿瘤及小鼠移植瘤进行成像;HER2阳性肿瘤光声信号较阴性肿瘤显著增高,作者认为该探针可作为光谱可区分的HER2乳腺肿瘤靶向体内光声造影剂。

要点

  • TRA-Aurelia-1吸收峰780 nm、TRA-Aurelia-2吸收峰720 nm,两者光谱可区分。
  • 人HER2阳性乳腺肿瘤经TRA-Aurelia-1或2处理后光声信号分别增高28.8倍和29.5倍(P = .002)。
  • 小鼠DY36T2Q肿瘤经TRA-Aurelia-1和2处理后光声信号较MDA-MB-231对照分别增高14.8倍和20.8倍(P < .001)。

核心结论

  • 研究显示TRA-Aurelia-1和2纳米颗粒可作为光谱可区分的HER2乳腺肿瘤靶向体内光声造影剂。

研究设计与样本

  • 研究论文;新鲜切除的人HER2阳性(n = 6)和HER2阴性三阴性乳腺癌肿瘤(n = 6)经TRA-Aurelia-1和2处理2小时后行MSOT成像;HER2表达DY36T2Q细胞和HER2阴性MDA-MB-231细胞原位植入小鼠(n = 5),注射后6小时行MSOT成像,采用Friedman检验分析。

关键影像表现/征象

  • TRA-Aurelia-1吸收峰780 nm、TRA-Aurelia-2吸收峰720 nm,两者光谱可区分。
  • 人HER2阳性乳腺肿瘤经TRA-Aurelia-1处理后光声信号增高28.8倍,经TRA-Aurelia-2处理后增高29.5倍(P = .002),均相对HER2阴性肿瘤。
  • 小鼠DY36T2Q肿瘤经TRA-Aurelia-1处理后光声信号较MDA-MB-231对照增高14.8倍(P < .001),经TRA-Aurelia-2处理后增高20.8倍(P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To develop optoacoustic, spectrally distinct, actively targeted gold nanoparticle-based near-infrared probes (trastuzumab [TRA], TRA-Aurelia-1, and TRA-Aurelia-2) that can be individually identifiable at multispectral optoacoustic tomography (MSOT) of human epidermal growth factor receptor 2 (HER2)-positive breast tumors. Materials and Methods Gold nanoparticle-based near-infrared probes (Aurelia-1 and 2) that are optoacoustically active and spectrally distinct for simultaneous MSOT imaging were synthesized and conjugated to TRA to produce TRA-Aurelia-1 and 2. Freshly resected human HER2-positive (n = 6) and HER2-negative (n = 6) triple-negative breast cancer tumors were treated with TRA-Aurelia-1 and TRA-Aurelia-2 for 2 hours and imaged with MSOT. HER2-expressing DY36T2Q cells and HER2-negative MDA-MB-231 cells were implanted orthotopically into mice (n = 5). MSOT imaging was performed 6 hours following the injection, and the Friedman test was used for analysis. Results TRA-Aurelia-1 (absorption peak, 780 nm) and TRA-Aurelia-2 (absorption peak, 720 nm) were spectrally distinct. HER2-positive human breast tumors exhibited a significant increase in optoacoustic signal following TRA-Aurelia-1 (28.8-fold) or 2 (29.5-fold) (P = .002) treatment relative to HER2-negative tumors. Treatment with TRA-Aurelia-1 and 2 increased optoacoustic signals in DY36T2Q tumors relative to those in MDA-MB-231 controls (14.8-fold, P < .001; 20.8-fold, P < .001, respectively). Conclusion The study demonstrates that TRA-Aurelia 1 and 2 nanoparticles operate as a spectrally distinct HER2 breast tumor-targeted in vivo optoacoustic agent. Keywords: Molecular Imaging, Nanoparticles, Photoacoustic Imaging, Breast Cancer Supplemental material is available for this article. © RSNA, 2023.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Samykutty A, Thomas KN, McNally M, et al. Simultaneous Detection of Multiple Tumor-targeted Gold Nanoparticles in HER2-Positive Breast Tumors Using Optoacoustic Imaging. Radiol Imaging Cancer. 2023. PMID: 37233208. doi:10.1148/rycan.220180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。